In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice
Summary
This summary is machine-generated.Pentoxifylline (PTX) treatment reduced atherosclerosis in mice by inhibiting the pro-inflammatory T helper 1 (Th1) immune response. This suggests Th1 polarization is detrimental and PTX offers a potential therapeutic strategy for atherosclerosis.
Area Of Science
- Immunology
- Cardiovascular Disease
- Pharmacology
Background
- Atherosclerosis involves a chronic immune response with T helper 1 (Th1) lymphocyte activation.
- The role of Th1 activation in atherosclerosis (protective or detrimental) is not fully understood.
Purpose Of The Study
- To investigate the effect of pentoxifylline (PTX), a Th1 differentiation inhibitor, on atherosclerosis in apolipoprotein E-deficient (apoE(-/-)) mice.
- To determine if modulating the Th1 immune response impacts atherosclerotic lesion development.
Main Methods
- Atherosclerosis-prone apoE(-/-) mice were treated with PTX or PBS (control) for 4 or 12 weeks.
- Immune responses, specifically Th1 lymphocyte polarization and cytokine production (IFN-gamma, IL-10), were analyzed.
- Atherosclerotic lesion size was quantified and correlated with immune cell populations.
Main Results
- Twelve-week PTX treatment significantly reduced atherosclerotic lesion size by 60% compared to controls.
- PTX-treated mice exhibited limited fatty streaks, while controls developed mature fibrofatty lesions.
- PTX treatment reduced the proportion of interferon (IFN)-gamma-producing Th1 splenic lymphocytes and promoted Th2 polarization by increasing IL-10 production.
Conclusions
- Pentoxifylline (PTX) protects against atherosclerosis by reducing Th1 polarization of T helper lymphocytes.
- The Th1 immune response in atherosclerosis is demonstrated to be deleterious.
- Modulating the Th1 differentiation pathway with agents like PTX represents a potential new pharmacological approach for treating atherosclerosis.
View abstract on PubMed